What do systematic reviews say?

Steroids vs vitamin D

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Steroids vs vitamin D

Steroid probably leads to lower number of participants withdrawing due to adverse events (AE) compared with vitamin D (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 0.22 [0.11, 0.42]
  4 studies · 2291 participants
  Moderate

Steroids vs vitamin D

Steroid probably leads to higher number of participants achieving 'response' by PGA compared with vitamin D (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 1.48 [1.28, 1.72]
  3 studies · 1827 participants
  Moderate

Steroid plus vitamin D vs steroids

Steroid plus vitamin D probably leads to higher number of participants achieving 'clearance' by IGA compared with steroid (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 1.22 [1.08, 1.36]
  4 studies · 2474 participants
  Moderate

Steroid plus vitamin D vs steroids

Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with steroid (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 1.15 [1.06, 1.25]
  3 studies · 2444 participants
  Moderate

Steroid plus vitamin D vs steroids

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Steroid plus vitamin D vs steroids

Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).

• Topical treatments for scalp psoriasis 2016 · Cochrane Headline outcomes only
  RR 0.88 [0.42, 1.88]
  3 studies · 2433 participants
  Moderate

Terbinafine 1% cream/gel vs Placebo (vehicle cream)

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 330 participants
  Low

Naftifine 1% cream once or twice daily vs placebo cream once or twice daily

Naftifine 1% cream once or twice daily showed no clear difference in relapse or recurrence Evidence of clinical or mycological infection… compared with placebo cream once or twice daily (low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.07 [0, 1.25]
  1 study · 44 participants
  Low

Naftifine 1% cream once or twice daily vs placebo cream once or twice daily

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Naftifine 1% cream once or twice daily vs placebo cream once or twice daily

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Azoles vs allylamines

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 638 participants
  Very low

Azoles vs allylamines

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 605 participants
  Very low

Azoles vs allylamines

It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with allylamines (very low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.7 [0.18, 2.68]
  5 studies · 386 participants
  Very low

Azoles vs allylamines

It is very uncertain whether azoles changes relapse or recurrence Evidence of clinical and mycological relapse… compared with allylamines (very low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 2.33 [0.21, 26.23]
  3 studies · 105 participants
  Very low

Azoles vs allylamines

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Azoles vs allylamines

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 7 participants
  Very low

Azoles vs moderate‐potent corticosteroid/azole combinations

Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.99 [0.93, 1.05]
  6 studies · 625 participants
  Low

Terbinafine 1% cream/gel vs Placebo (vehicle cream)

Terbinafine 1% cream/gel may leads to higher clinical cure Resolution of clinical signs and symptoms. Treatment… compared with placebo cream/gel (low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 4.51 [3.1, 6.56]
  5 studies · 273 participants
  Low

Azoles vs moderate‐potent corticosteroid/azole combinations

It is very uncertain whether azoles changes clinical cure (immediately at end of treatment) Resolution of… compared with moderate‐potent corticosteroid/azole combinations (very low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.67 [0.53, 0.84]
  4 studies · 353 participants
  Very low